4.2 Article

Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection

Journal

JOURNAL OF CHEMOTHERAPY
Volume 33, Issue 3, Pages 193-197

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/1120009X.2020.1775424

Keywords

Lopinavir; ritonavir; CoVID-19; SARS-COV-2

Ask authors/readers for more resources

The study suggests that lopinavir/ritonavir may reduce the viral carriage period in CoVID-19 patients and decrease lymphocyte reduction and increased ferritin levels. Further research is needed to evaluate the effectiveness of lopinavir/ritonavir in treating SARS-CoV-2 infected patients.
Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen, while group B did not. Lymphocytes were more significantly increased in patients of group A. Ferritin serum levels were also decreased significantly in these patients. Number of days needed for a first negative result of Real Time- Polymerase Chain Reaction (RT-PCR) was lower for Group A. The present study suggests that lopinavir/ritonavir may reduce the viral carriage in a shorter period of time compared with other antiviral regimens. Further studies are needed in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available